Camoteskimab for Eczema
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to test the effectiveness and safety of a new treatment called camoteskimab for individuals with moderate to severe eczema, a condition that causes itchy, inflamed skin. Participants will receive either one of two different doses of camoteskimab or a placebo (a dummy treatment) to compare results. It suits adults who have had eczema for at least a year, experience significant skin involvement, and have not found success with topical treatments. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.
Will I have to stop taking my current medications?
The trial protocol does not specify if you must stop taking your current medications. However, if you are using certain systemic therapies for eczema, you may need to stop them before joining the trial.
Is there any evidence suggesting that camoteskimab is likely to be safe for humans?
Research has shown that camoteskimab was safe in earlier studies. Patients who took camoteskimab experienced significant improvement in their eczema symptoms, indicating the treatment's effectiveness. These studies did not identify any major side effects associated with the treatment. Camoteskimab is currently in a Phase 2 trial, which means it has already passed initial safety tests. This phase examines its safety and effectiveness in a larger group of patients. Overall, the treatment appears well-tolerated, but ongoing studies will provide more detailed safety information.12345
Why do researchers think this study treatment might be promising?
Researchers are excited about Camoteskimab for eczema because it offers a potentially new way to tackle the condition. Most current treatments, like topical steroids and calcineurin inhibitors, focus on reducing inflammation and suppressing the immune response. However, Camoteskimab is thought to work by specifically targeting and modulating certain pathways of the immune system that are involved in eczema, possibly leading to more precise treatment. This precision might mean fewer side effects and better outcomes for patients. Additionally, the introduction of Camoteskimab could provide an option for those who have not responded well to existing treatments.
What evidence suggests that camoteskimab might be an effective treatment for eczema?
Research has shown that camoteskimab holds promise for treating eczema. Studies found that patients taking camoteskimab experienced noticeable improvement in eczema symptoms and affected skin areas. The treatment was well tolerated, with no serious side effects linked to the medication. This trial will evaluate different doses of camoteskimab to determine its effectiveness and safety, suggesting that camoteskimab could be an effective option for people with moderate to severe eczema.13467
Are You a Good Fit for This Trial?
Adults with moderate to severe atopic dermatitis (a type of eczema) can join this study. Participants must meet certain health standards, which are not specified here.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment (Blinded Period)
Participants are randomized to receive either camoteskimab dose 1, camoteskimab dose 2, or placebo
Extension Period (Open-label)
All participants receive camoteskimab
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Camoteskimab
Trial Overview
The trial is testing the effects of a drug called Camoteskimab against a placebo (a substance with no active drug). It's a blind test, so participants won't know which one they're getting. The goal is to see if Camoteskimab helps with their skin condition.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Placebo Group
Camoteskimab
Camoteskimab
Dummy version of the study drug
Find a Clinic Near You
Who Is Running the Clinical Trial?
Apollo Therapeutics Ltd
Lead Sponsor
Citations
NCT06436183 | A Study of the Effects of Camoteskimab in ...
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of ...
2.
apollotx.com
apollotx.com/news/apollo-therapeutics-anti-il-18-antibody-camoteskimab-met-the-primary-endpoint/Apollo Therapeutics' Anti-IL-18 Antibody Camoteskimab ...
Patients receiving camoteskimab had a clinically meaningful and statistically significant reduction in mean EASI score at week 16 compared ...
Camoteskimab - Drug Targets, Indications, Patents
In the trial, treatment with camoteskimab yielded a statistically significant reduction in patients\' eczema area and severity scores compared ...
Apollo's $15M bet on IL-18 antibody pays off with phase 2 ...
Apollo's $15 million bet on Avalo's anti-IL-18 monoclonal antibody appears to have paid off after the therapy aced a dermatitis trial.
camoteskimab (AVTX-007) / Avalo Therap, AstraZeneca, ...
... Camoteskimab was extremely well tolerated with no treatment-related serious adverse events or discontinuations." P2a data • Atopic Dermatitis. Print; Email ...
A Study of the Effects of Camoteskimab in Adults ...
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and ...
Camoteskimab: Uses, Interactions, Mechanism of Action
... Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis ... outcomes with our structured adverse effects data. See a data sample.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.